Q3 Loss Widens to $51.8M as Cash Drops $39.7M; PROACT 1 Readout Set for Q2 2027
PROK sits 32% above its 52-week low of $0.87.
Summary
ProKidney's Q3 net loss widened to $51.8M from $35.8M a year earlier, with R&D spending up to $40.8M from $26.8M as PROACT 1 Phase 3 work and manufacturing costs ramp. Cash, equivalents and marketable securities fell to $141.9M at September 30 from $181.6M at June 30 — a $39.7M quarterly burn. Management still says that liquidity funds operations into mid-2027, consistent with the 8-K filed November 9th, and the $200M Jefferies at-the-market program filed October 29th remains the main funding lever if burn stays at this pace. The pivotal PROACT 1 topline eGFR-slope readout is on track for Q2 2027; that data, not the quarterly loss, is what determines whether the current cash position is enough.
At the time of this announcement, PROK was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $347.7M. The 52-week trading range was $0.87 to $2.88. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.